Literature DB >> 24563902

In the wake of Angelina - managing a family history of breast cancer.

Kate Dunlop1, Judy Kirk, Kathy Tucker.   

Abstract

BACKGROUND: Accurate risk assessment by general practitioners (GPs) of breast and ovarian cancer for unaffected women with a family history is important to ensure appropriate referral. Family cancer clinics can provide significant benefits for those at high risk, but genetic testing is unlikely to benefit those who are unaffected, or have little or no family history. The overwhelming increase in referrals following celebrity Angelina Jolie's decision to have a risk-reducing mastectomy because she carries a gene mutation has put pressure on services.
OBJECTIVE: To provide information for GPs about managing women with concerns about their family history of breast cancer and highlight the resources available. DISCUSSION: GPs are well placed to assess risk of breast and ovarian cancer and are encouraged to use the available resources to assist them in appropriate risk assessment and referral.

Entities:  

Mesh:

Year:  2014        PMID: 24563902

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  4 in total

1.  Trends in Use of Risk-Reducing Mastectomy in a Context of Celebrity Decisions and Media Coverage: An Observational Study in the United States and Australia.

Authors:  Jialin Mao; Louisa Jorm; Art Sedrakyan
Journal:  Health Serv Res       Date:  2017-09-25       Impact factor: 3.402

2.  Twitter and Non-Elites: Interpreting Power Dynamics in the Life Story of the (#)BRCA Twitter Stream.

Authors:  Stefania Vicari
Journal:  Soc Media Soc       Date:  2017-09-23

3.  Familial breast cancer: Genetic counseling over time, including patients´ expectations and initiators considering the Angelina Jolie effect.

Authors:  Christina Evers; Christine Fischer; Nicola Dikow; Sarah Schott
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

Review 4.  Precision Medicine, AI, and the Future of Personalized Health Care.

Authors:  Kevin B Johnson; Wei-Qi Wei; Dilhan Weeraratne; Mark E Frisse; Karl Misulis; Kyu Rhee; Juan Zhao; Jane L Snowdon
Journal:  Clin Transl Sci       Date:  2020-10-12       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.